Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
Checkmate Pharmaceuticals, a clinical stage biopharmaceutical company (Nasdaq: CMPI), announced a live webcast on innate immune modulators and its product vidutolimod (CMP-001) on October 26, 2021. The event, moderated by Jefferies, features Dr. Jason Luke and Dr. Art Krieg discussing the potential of innate immune modulation in cancer therapy, specifically targeting melanoma and other cancers. Vidutolimod, an advanced TLR9 agonist, is currently in late-stage trials. An archived version of the webcast will be available for 90 days on Checkmate's website.
- Vidutolimod (CMP-001) is in late-stage clinical trials, indicating potential advancement in cancer treatment.
- Webcast features recognized experts, enhancing credibility and visibility for the company.
- None.
Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET
Featured speakers include Jason Luke, M.D., FACP and Art Krieg, M.D.
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced a live webcast on innate immune modulators and vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00am – 12:00pm ET.
The webcast will be moderated by Maury Raycroft, Ph.D. and feature Jason Luke, M.D., FACP and Art Krieg, M.D. in a scientific discussion of the role of innate immune modulators in cancer treatment. Dr. Luke will review the various approaches to modulate innate immunity for the treatment of cancer and the challenges experienced by the field. Dr. Krieg will discuss the unique modality and mechanism of action of vidutolimod, a biologic, advanced generation Toll-like receptor 9 (TLR9) agonist, which is in late-stage clinical trials for patients with melanoma and proof-of-concept clinical trials for patients with head and neck cancer, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.
Dr. Luke is an internationally recognized clinical and translational investigator in melanoma and early drug development, particularly immuno-oncology. Dr Krieg is the Founder and Chief Scientific Officer of Checkmate Pharmaceuticals, Inc. He has published more than 250 scientific papers and is an inventor on more than 50 issued U.S. patents covering oligonucleotide technologies.
The webcast can be accessed under “Events & Presentations” in the Investors section of the Checkmate website. An archived copy of the webcast will be available on the Checkmate website for approximately 90 days after the event.
About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.
Availability of Other Information About Checkmate Pharmaceuticals
Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Forward Looking Statements
Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. These statements include those regarding vidutolimod (CMP-001), including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for vidutolimod and the benefits and related implications of current and future partnerships and/or collaborations; and expectations regarding the Company’s use of capital, expenses and other financial results. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the three months ended June 30, 2021 and in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission which are available on the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.
FAQ
What is the date and time of the Checkmate Pharmaceuticals webcast?
Who are the featured speakers in the Checkmate Pharmaceuticals webcast?
What is vidutolimod (CMP-001) and its significance?
Where can I find the archived copy of the Checkmate Pharmaceuticals webcast?
